Literature DB >> 22725699

Germline RAD51C mutations in ovarian cancer susceptibility.

F Coulet1, A Fajac, C Colas, M Eyries, A Dion-Minière, R Rouzier, S Uzan, J-P Lefranc, M Carbonnel, F Cornelis, A Cortez, F Soubrier.   

Abstract

Several genes might explain BRCA1/2 negative breast and ovarian family cases. Deleterious mutations in few genes involved in the Fanconi complex are responsible for Fanconi anemia at the homozygous state and breast cancer (BC) susceptibility at the heterozygous state (BRCA2, PALB2, BRIP1). RAD51C plays an important role in the double-strand break repair pathway and a biallelic missense mutation in the RAD51C gene was found in a Fanconi anemia-like disorder. Subsequently, six monoallelic pathogenic mutations were identified after screening 480 BRCA1/2 negative breast and ovarian cancer (BC/OC) pedigrees. Several reports were unsuccessful to replicate these results. To investigate whether germline mutations in RAD51C are associated with an increased risk of developing BC/OC, we screened, by Sanger sequencing of the coding sequence, 117 index cases of breast and ovarian families from French or European origin, and negative for BRCA1/2 mutations. In our study, we found 3 pathogenic mutations among 117 families screened which corresponds to a 2.6% frequency. Our results confirm that RAD51C is a susceptibility gene for ovarian and BC and that this gene should be screened for mutations in families with multiple BC/OC.
© 2012 John Wiley & Sons A/S. Published by Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22725699     DOI: 10.1111/j.1399-0004.2012.01917.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  16 in total

1.  Rapid and cost effective screening of breast and ovarian cancer genes using novel sequence capture method in clinical samples.

Authors:  Kristóf Arvai; Péter Horváth; Bernadett Balla; Anna M Tőkés; Bálint Tobiás; István Takács; Zsolt Nagy; Péter Lakatos; János P Kósa
Journal:  Fam Cancer       Date:  2014-12       Impact factor: 2.375

Review 2.  Recent advances in targeting DNA repair pathways for the treatment of ovarian cancer and their clinical relevance.

Authors:  Katsutoshi Oda; Michihiro Tanikawa; Kenbun Sone; Mayuyo Mori-Uchino; Yutaka Osuga; Tomoyuki Fujii
Journal:  Int J Clin Oncol       Date:  2017-05-15       Impact factor: 3.402

Review 3.  Genetic counseling for Fanconi anemia: crosslinking disciplines.

Authors:  Heather A Zierhut; Rebecca Tryon; Erica M Sanborn
Journal:  J Genet Couns       Date:  2014-09-20       Impact factor: 2.537

4.  Contribution of germline deleterious variants in the RAD51 paralogs to breast and ovarian cancers.

Authors:  Lisa Golmard; Laurent Castéra; Sophie Krieger; Virginie Moncoutier; Khadija Abidallah; Henrique Tenreiro; Anthony Laugé; Julien Tarabeux; Gael A Millot; André Nicolas; Marick Laé; Caroline Abadie; Pascaline Berthet; Florence Polycarpe; Thierry Frébourg; Camille Elan; Antoine de Pauw; Marion Gauthier-Villars; Bruno Buecher; Marc-Henri Stern; Dominique Stoppa-Lyonnet; Dominique Vaur; Claude Houdayer
Journal:  Eur J Hum Genet       Date:  2017-11-08       Impact factor: 4.246

5.  Genetic characterization of early onset ovarian carcinoma.

Authors:  Sarah S Bernards; Barbara M Norquist; Maria I Harrell; Kathy J Agnew; Ming K Lee; Tom Walsh; Elizabeth M Swisher
Journal:  Gynecol Oncol       Date:  2015-12-21       Impact factor: 5.482

6.  Exceptional response to FOLFIRINOX in a patient with pancreatic cancer and a germline RAD51C mutation.

Authors:  Sofia Palacio; Terri Pollack; Rachel Silva-Smith; Daniel A Sussman; Peter J Hosein
Journal:  J Gastrointest Oncol       Date:  2018-08

Review 7.  The inherited bone marrow failure syndromes.

Authors:  S Deborah Chirnomas; Gary M Kupfer
Journal:  Pediatr Clin North Am       Date:  2013-12       Impact factor: 3.278

Review 8.  Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer.

Authors:  Angela George; Stan Kaye; Susana Banerjee
Journal:  Nat Rev Clin Oncol       Date:  2016-12-13       Impact factor: 66.675

9.  Thiopurine-induced mitotic catastrophe in Rad51d-deficient mammalian cells.

Authors:  Michael D Wyatt; Nicole M Reilly; Shikha Patel; Preeti Rajesh; Gary P Schools; Phillip G Smiraldo; Douglas L Pittman
Journal:  Environ Mol Mutagen       Date:  2017-09-25       Impact factor: 3.579

10.  A recurrent pathogenic BRCA2 exon 5-11 duplication in the Christian Arab population in Israel.

Authors:  Hagit Baris-Feldman; Karin Weiss; Gili Reznick Levi; Gal Larom; Vered Ofen Glassner; Nina Ekhilevitch; Nitzan Sharon Swartzman; Tamar Paperna
Journal:  Fam Cancer       Date:  2021-05-17       Impact factor: 2.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.